1. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
- Author
-
Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, McDonald TP, O'Brien J, Renger JJ, Williams PD, Winrow CJ, and Coleman PJ
- Subjects
- Animals, Drug Discovery, Humans, Piperidines pharmacokinetics, Rats, Rats, Transgenic, Structure-Activity Relationship, Orexin Receptor Antagonists chemistry, Orexin Receptor Antagonists pharmacology, Orexin Receptors metabolism, Piperidines chemistry, Piperidines pharmacology
- Abstract
While a correlation between blockade of the orexin 2 receptor (OX
2 R) with either a dual orexin receptor antagonist (DORA) or a selective orexin 2 receptor antagonist (2-SORA) and a decrease of wakefulness is well established, less is known about selective blockade of the orexin 1 receptor (OX1 R). Therefore, a highly selective orexin 1 antagonist (1-SORA) with suitable properties to allow in vivo interrogation of OX1 R specific pharmacology in preclinical species remains an attractive target. Herein, we describe the discovery of an optimized 1-SORA series in the piperidine ether class. Notably, a 4,4-difluoropiperidine core coupled with a 2-quinoline ether linkage provides OX1 R selective compounds. The combination with an azabenzimidazole or imidazopyridine amide substituent leads to analogs 47 and 51 with >625-fold functional selectivity for OX1 R over OX2 R in rat. Compounds 47 and 51 possess clean off-target profiles and the required pharmacokinetic and physical properties to be useful as 1-SORA tool compounds., (Copyright © 2016 Elsevier Ltd. All rights reserved.)- Published
- 2016
- Full Text
- View/download PDF